Niksan Pharmaceutical is worldâs leading manufacturer, trader,exporter and supplier of the GranisetronAPI and Granisetron formulations. Niksan Pharmaceutical manufactures largequantity of Granisetron API and finished products in Ankleshwar, Gujarat,India. Niksan Pharmaceutical and Niksan group companies are the largestmanufacturers and suppliers of Granisetron products.
Niksan Pharmaceutical exporting very big quantity of the finesquality products of Granisetron inall over world for many years in acountries like Romania, Finland, Malaysia, Netherland, South Africa, Brazil,Egypt, Singapore, Jordan, Lebanon, Israel, Vietnam, Bangladesh, Paraguay,Argentina, Dominican Republic, Sudan, Hong Kong, Seychelles, Algeria,Iran,Uruguay, Russia, Thailand, Afghanistan, Latvia, Lithuania, United ArabEmirates, Seychelles, Peru, Switzerland, Tunisia, France, Hungary, Finland,Turkey, Pakistan, Rwanda, South Africa, Denmark, Malawi, Croatia, Slovenia,Ireland, Zambia, Cyprus, Nigeria, Uzbekistan, Cameroon, Netherlands,Azerbaijan, Venezuela, Morocco, Cote D Ivoire, St Lucia, South Korea, Congo,Philippines, Colombia Sweden, Hungary, Mauritius, Vanuatu, Malta, Kazakistan,Slovenia, Bolivia, Japan, Uganda, Australia and many more countries.
Niksan Pharmaceutical also supply large quantity of Granisetron products in Indian stateslike Gujarat, Haryana, Rajasthan, Madhya Pradesh, Kerala, Tamilnadu, Delhi,Bihar, Uttar Pradesh, Assam, Goa, Hyderabad, Telangana, Mizoram, Sikkim etc.
Granisetron belongs to the class of 5-HT3 receptorantagonist. Granisetron prevents nausea and vomiting by serotonin which is anatural substance which can cause nausea and vomiting.
Granisetron used as an antiemetic agent to treatvomiting and nausea in the treatment like chemotherapy. This drug did not haveeffect in motion sickness and it will not effect on dopamine receptors.
SYNONYMS OF GRANISETRON: GranisÃ©tron, GranisetrÃ³n, Granisetron,Granisetronum
IUPAC NAME: 1-Methyl-N-((1R, 3r, 5S)-9-methyl-9-azabicyclononan-3-yl)-1H-indazole-3-carboxamide
CAS NO: 109889-09-0
MOLECULAR FORMULA: C18H24N4O
MOLECULAR MASS: 312.41 g/mol
STORAGE OF GRANISETRON: Keep medication is cooland dry place, do not store in bathroom or kitchen. Keep all medication awayfrom children and pets.
HOW TO USE: Granisetron comes in oral dosage form liketablet; it is consumed by mouth with water. Take the medicine 1hr before thechemotherapy. And take second dose after the 12hr interval of first dose.
HOW GRANISETRON WORKS: Granisetron givesantiemetic activity by inhibiting the 5-HT3 receptor which are located incentrally and peripherally in the body. By this process the natural serotoninsecretion inhibited and by this the nausea and vomiting is prevented.
PHARMACOKINETICS OF GRANISETRON: The mainabsorption of Granisetron is done by the oral and it is rapid and complete. Asthe result of first pass metabolism the oral bioavaibility is reduced about60%. The half-life of Granisetron in the cancer patients is 9-12hrs and in thenormal patient the half-life is 4-6hrs. The 48% excretion of Granisetron isdone by urination and remaining will excreted in faces.
SIDE EFFECTS OF GRANISETRON: There aresome common side effects of Granisetron is headache, dizziness, fever, pain,redness and swelling on the injection point. Tell your doctor if you see sideeffects like stomach/abdominal pain, chest pain, fast irregular heartbeats,hallucination, loss of coordination, muscle pain etc. The allergic reactions bythe Granisetron are rare but if you develop symptoms like rash, itching orirritation consult your doctor.
PRECAUTIONS: Tell your doctor if you are allergic toGranisetron or its residues. Before using the Granisetron tell your doctor ifyou have any past related to stomach or intestinal problem like swelling orsurgery. Tell your doctor if you have certain history related to heartproblems. Talk to your doctor about taking Granisetron safely.
CDSCO APPROVAL OF GRANISETRON: Granisetrontablets are approved by CDSCO in India in 05.07.2000
FORMULATIONS AVAILABLE IN MARKET:
Note: Product protected by validpatents are not offered for sale in countries where such patents are stillvalid and its liability is at Buyers Risk